Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year

For the second quarter in a row, Incyte has used its earnings results to significantly slim down its early-stage pipeline as the Jakafi-maker channels its resources toward “high potential impact programs.”